Hayward Holdings Q2 sales rise 6%, beat estimates
Reuters2026/07/29 11:14
Overview
Specialty water management firm's fiscal Q2 sales rose 6%, beating analyst expectations
Adjusted net income and adjusted EBITDA for Q2 both beat analyst expectations
Company attributes growth to strong price realization and stable volume
Outlook
Hayward Holdings maintains 2026 net sales guidance for about 5% growth from 2025
Company expects 2026 adjusted diluted EPS of $0.84 to $0.87, up 9% to 13% from 2025
Hayward says outlook supported by positive price realization and technology adoption
Result Drivers
PRICE REALIZATION - Co said Q2 sales growth was driven by positive net price to offset inflation and tariffs
NORTH AMERICA VOLUME AND PRICE - North America segment sales rose on higher prices and increased volume
INTERNATIONAL VOLUME DECLINE - Europe & Rest of World sales fell due to lower volume, mainly from geopolitical conflicts in the Middle East
Company press release: ID:nBw1fN9MQa
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 Sales |
Beat |
$318.40 mln |
$304.60 mln (9 Analysts) |
Q2 Adjusted Net Income |
Beat |
$57.80 mln |
$56.17 mln (7 Analysts) |
Q2 Adjusted EBITDA |
Beat |
$92.70 mln |
$89.23 mln (9 Analysts) |
Q2 Adjusted EBITDA Margin |
|
29.10% |
|
Q2 Operating Income |
|
$76 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the industrial machinery & equipment peer group is "buy"
Wall Street's median 12-month price target for Hayward Holdings Inc is $17.00, about 12.5% above its July 28 closing price of $15.11
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 15 three months ago
Reuters Recommended Reads
July 28 - Veralto Q2 results beat estimates on industrial water treatment demand; raises outlook
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - Heard on the Street -- WSJ
NASDAQ TRADE HALT CONTINUES <EFTY.O> REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES <UCFIW.O> REASON NOT AVAILABLE AT 03:28 AM